UK markets close in 1 hour 26 minutes

Biocartis Group NV (BIOGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.50000.0000 (0.00%)
As of 09:16AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.5000
Open4.5000
BidN/A x N/A
AskN/A x N/A
Day's range4.5000 - 4.5000
52-week range4.5000 - 4.5000
Volume200
Avg. volume0
Market cap258.956M
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)-1.3640
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

    PRESS RELEASE: REGULATED INFORMATION10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced the Company has achieved its 2021 key business objectives which were focused on three performance indicators: expanded installed base of its rapid and easy-to-use Idylla™ molecular diagnostics platform, increased Idylla™ commercial

  • Globe Newswire

    Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant

    PRESS RELEASE: 9 December 2021, 07:00 CET Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Mechelen, Belgium, 9 December 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the Company performed an in-silico analysis which concluded that the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™ SARS-CoV-2/Flu/RSV1 Panel (CE-IVD) detect the currently available B.1.1.529/Omicron

  • Globe Newswire

    Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA

    PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the US Food and Drug Administration (FDA) has granted 510(k) clearance1 for SeptiCyte® RAPID (CE-IVD, US FDA 510(k)). This test runs on Biocartis’ rapid and easy-to-use molecular diagnostics Idylla™ platform2 and was devel